Novel Cancer Immunotherapy Drug Given To First Patient In Trial

Biond Biologics, a biotechnology company developing immunotherapy treatments for cancer, has announced that the first patient has received the novel BND-35 therapy as part of its first-in-human clinical trial.

BND-35, an antagonist antibody developed for the treatment of solid tumors, was administered at the Institute of Oncology at Rabin Medical Center’s Davidoff Center. The therapy is designed to suppress the spread of tumors. 

The hospital in Petah Tikva is one of the six sites in Israel and the US involved in the trial. 

The study will examine the safety, tolerability, anti-tumor activity, pharmacokinetics and exploratory biomarkers for BND-35 both as a monotherapy and in combination with two other approved drugs. 

“The BND-35 trial design introduces a novel combination therapy that targets the immunosuppressive cell milieu within the tumor microenvironment (TME),” said Prof. Salomon Stemmer, Head of Research, Development and Innovation and Deputy Director of the Davidoff Center, and a clinical investigator in the trial. 

“There’s a pressing need for innovative treatments for cancers that are resistant to existing therapies. Given its promising preclinical efficacy, we’re eager to assess BND-35’s potential in overcoming ILT3/LILRB4-mediated immunosuppression,” he said.